SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In contrast, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists have shown strong effectiveness in reducing liver fat and resolving NASH, positioning them as promising treatments for MASLD.